E20 Diffusion Tensor Imaging In Huntington's Disease: Impact Of The Control For Corrupted Data In Comparisons At The Group Level

Müller, HP; Kassubek, Jan; Grön, Georg; Sprengelmeyer, Reiner; Hobbs, NZ; Roos, R. A. C.; Duerr, A; Tabrizi, Sarah J.; Süssmuth, SD; Orth, Michael; Landwehrmeyer, G. Bernhard

doi:10.1136/jnnp-2014-309032.123

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also the basal ganglia, the surrounding white matter tracts between these regions and the cortex have been analyzed thoroughly using DTI. There have been studies looking at both white matter and gray matter, showing an increase of FA in the gray matter and a decrease of FA in the white matter for HD patients compared to controls [95][96][97][98][99][100][101][102][103]. Other studies showed that diffusion imaging could be used as a method to differentiate the subgroup close-to-onset premanifest HDEGC from far-from-onset HDEGC.…”

Section: Diffusion Tensor Imagingmentioning

confidence: 99%

Neuroimaging Biomarkers for Huntington’s Disease

Zande¹,

Ghariq²,

Bresser³

et al. 2022

From Pathophysiology to Treatment of Huntington's Disease

View full text Add to dashboard Cite

Biomarkers are of great importance in the prediction of onset and follow-up of patients with Huntington’s disease (HD). Neuroimaging is a convenient biomarker, because of its non-invasive character. Since technology is continuously evolving, we are increasingly able to visualize detailed neural structures and functions. Furthermore, it could also identify new targets for therapeutic interventions. In this chapter, we review findings in neuroimaging research applied to HD. First, we will describe the neuroanatomical structures and cellular processes, which are important in the pathophysiology of HD and are therefore particularly interesting to focus on. We will then discuss the different imaging modalities; from structural to functional, from commonly used to novel imaging strategies. Striatal- and cortical-volume loss on conventional MRI and decrease in uptake of radiotracers on PET are currently the most robust markers of disease progression. The use of other MRI-metabolites, specific PET radioligands, DTI, and fMRI may have the potential to detect HD pathology earlier and more accurately but needs further investigation. These neuroimaging markers, possibly combined, can be useful clinical outcome measures in clinical trials and could improve the management and treatment of future patients.

show abstract